Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 4,300 shares of the business’s stock in a transaction that occurred on Wednesday, November 16th. The stock was acquired at an average price of $10.13 per share, with a total value of $43,559.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $31,088,473.63. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Friday, November 11th, Phillip Md Et Al Frost purchased 14,600 shares of Opko Health stock. The stock was acquired at an average price of $9.46 per share, with a total value of $138,116.00.
  • On Wednesday, November 9th, Phillip Md Et Al Frost purchased 5,400 shares of Opko Health stock. The stock was acquired at an average price of $9.33 per share, with a total value of $50,382.00.
  • On Tuesday, November 8th, Phillip Md Et Al Frost purchased 23,100 shares of Opko Health stock. The stock was acquired at an average price of $9.22 per share, with a total value of $212,982.00.
  • On Wednesday, November 2nd, Phillip Md Et Al Frost purchased 10,000 shares of Opko Health stock. The stock was acquired at an average price of $9.48 per share, with a total value of $94,800.00.
  • On Tuesday, November 1st, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.49 per share, for a total transaction of $94,900.00.
  • On Monday, October 31st, Phillip Md Et Al Frost acquired 11,800 shares of Opko Health stock. The stock was purchased at an average price of $9.43 per share, for a total transaction of $111,274.00.
  • On Friday, October 28th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.46 per share, for a total transaction of $94,600.00.
  • On Thursday, October 27th, Phillip Md Et Al Frost acquired 10,000 shares of Opko Health stock. The stock was purchased at an average price of $9.36 per share, for a total transaction of $93,600.00.
  • On Wednesday, October 26th, Phillip Md Et Al Frost acquired 5,600 shares of Opko Health stock. The stock was purchased at an average price of $9.27 per share, for a total transaction of $51,912.00.
  • On Tuesday, October 25th, Phillip Md Et Al Frost acquired 3,600 shares of Opko Health stock. The stock was purchased at an average price of $9.38 per share, for a total transaction of $33,768.00.

Opko Health Inc. (NASDAQ:OPK) traded down 0.526% on Friday, reaching $10.405. The company had a trading volume of 1,418,897 shares. The stock’s market capitalization is $5.80 billion. The stock has a 50 day moving average price of $9.77 and a 200 day moving average price of $9.86. Opko Health Inc. has a 52-week low of $7.12 and a 52-week high of $11.85.

Opko Health (NASDAQ:OPK) last issued its earnings results on Monday, November 7th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.03). Opko Health had a negative net margin of 0.81% and a negative return on equity of 0.49%. The company earned $298 million during the quarter, compared to analysts’ expectations of $322 million. During the same period last year, the company posted $0.25 earnings per share. The firm’s quarterly revenue was up 108.4% compared to the same quarter last year. Analysts expect that Opko Health Inc. will post ($0.08) EPS for the current year.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. LPL Financial LLC boosted its position in shares of Opko Health by 3.9% in the third quarter. LPL Financial LLC now owns 13,374 shares of the company’s stock worth $142,000 after buying an additional 504 shares during the period. Piedmont Investment Advisors LLC acquired a new position in shares of Opko Health during the third quarter worth $622,000. Finally, Price T Rowe Associates Inc. MD boosted its position in shares of Opko Health by 3.1% in the third quarter. Price T Rowe Associates Inc. MD now owns 947,871 shares of the company’s stock worth $10,038,000 after buying an additional 28,700 shares during the period. 20.30% of the stock is owned by institutional investors.

Several research analysts have recently weighed in on OPK shares. JPMorgan Chase & Co. set a $14.00 target price on Opko Health and gave the stock a “buy” rating in a report on Tuesday, August 9th. Jefferies Group restated a “hold” rating and set a $10.00 target price on shares of Opko Health in a report on Monday, October 10th. Oppenheimer Holdings Inc. restated a “market perform” rating on shares of Opko Health in a report on Thursday, August 11th. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Tuesday, October 25th. Finally, TheStreet cut Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, November 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $13.17.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NASDAQ:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.